Match Document Document Title
9062298 Antidotes for factor XA inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
9034822 Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds  
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
9034823 Medicament for therapeutic treatment and/or improvement of sepsis  
A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized...
9029324 Single-dose administration of Factor VIIa  
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between...
9023796 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antidotes for factor XA inhibitors and methods of using the same
 
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
9018166 Conjugated FVIII variants  
The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.
9018157 Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8  
Provided are methods for preventing and treating inflammation and organ injury after ischemia/reperfusion, and methods for treating lung injury, comprising administering a milk fat globule...
9018167 TFPI inhibitors and methods of use  
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance...
8999333 Human tissue factor antibody and uses thereof  
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to...
8987202 Factor VII or Factor VIIa Gla domain variants  
Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein...
8987190 Treatment of acute ischemic stroke or intracranial bleeding with tPa and carbamylated erythropoietin  
The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of...
8969295 Identifying and modulating molecular pathways that mediate nervous system plasticity  
The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in...
8951525 Human tissue factor antibody and uses thereof  
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to...
8951527 Radioprotectants targeting thrombospondin-1 and CD47  
Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect...
8932826 Method for simultaneously determining multiple coagulation proteases  
The present invention relates to a chromogenic method for simultaneously determining the activity of multiple coagulation proteases or for simultaneously determining the inhibition of multiple...
8921319 Serine protease inhibitors  
The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the...
8912143 Genetically modified TFPI and method of treating coagulation using the same  
The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites...
8865154 Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface  
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include...
8859526 Methods for treating bleeding disorders using sulfated polysaccharides  
Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with...
8846620 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides  
Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated...
8840877 Polysaccharide-protein conjugates reversibly coupled via imine bonds  
Method for preparing an oxidized polysaccharide-protein composition, by (a) oxidizing a polysaccharide with an oxidizing agent to form an oxidized polysaccharide where less than 20% of the...
8840879 Conjugates of hydroxyalkyl starch and a protein  
Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and...
8835384 Compositions and methods for obtaining cells to treat heart tissue  
This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the...
8835388 Polymer von Willebrand factor-conjugates  
The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to...
8821871 Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof  
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
8815250 Clotting factor-Fc chimeric proteins to treat hemophilia  
The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a...
8802620 Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A  
There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor...
8785387 Neuregulin based methods and compositions for treating cardiovascular disease  
The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly,...
8784816 Antibodies which bind factor VIII  
The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such...
8778870 Modified factor IX polypeptides and uses thereof  
Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that...
8772238 Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer  
The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris...
8772239 Medicament for therapeutic treatment and/or improvement of sepsis  
A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized...
8758822 Method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs  
The present invention relates to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, and more particularly, to a method for manufacturing uniform size...
8759294 Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof  
Tissue factor-bearing yeast derived microvesicles comprising a yeast membrane and a tissue factor protein, or a fragment thereof, or a tissue factor protein or a fragment thereof fused to another...
8759293 von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto  
The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.
8753631 Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders  
The present invention is directed to a therapeutic agent comprising a GPIIIa(49-66) specific targeting agent and a thrombi-specific homing agent. Also disclosed is the use of the therapeutic agent...
8741845 Lyophilized fibrin sealant for high volume hemorrhage  
ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or...
8729022 Stabilised solid compositions of factor VII polypeptides  
The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used...
8722624 Alpha-1-antitrypsin compositions and methods of use  
A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention,...
8715672 Treatment of diseases linked to pathological kinin formation  
The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional...
8703706 Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit  
The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The...
8703705 Modified factor VIII peptides  
The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognized by a...
8691211 Suppression of immune response to factor VIII in hemophilia A patients  
This invention relates to methods and compositions for suppressing an immune response to Factor VIII in subjects suffering from hemophilia A and having preformed inhibitor antibodies against...
8680052 Methods of treating, reducing the incidence of, and/or preventing ischemic events  
Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a...
8658597 Stabilised compositions of factor VII polypeptides  
The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these...
8652471 Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor  
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of...
8647620 Chimeric factor VII molecules  
The present invention relates to chimeric Factor VII polypeptides and methods of using the same.
8637448 Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface  
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include...
8628787 Method for producing a device applicable to biological tissues, particularly a patch for treating damaged tissues, and a device obtained by said method  
The present invention relates to a device consisting of cross-linked nanofibrillary fibrin supported on and rooted to a microporous nonwoven fabric consisting of a biocompatible synthetic polymer...
8628769 Modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...